In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
about
Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitorsNon-M variants of human immunodeficiency virus type 1.Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West AfricaGenotypic resistance profiles of HIV-2-treated patients in West Africa.HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.Re-testing and misclassification of HIV-2 and HIV-1&2 dually reactive patients among the HIV-2 cohort of the West African Database to evaluate AIDS collaborationNew sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA loadPolymorphisms of HIV-2 integrase and selection of resistance to raltegravirThree main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimensRevealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsCell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patientsHIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes.Update on human immunodeficiency virus (HIV)-2 infection.HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.A modular system to evaluate the efficacy of protease inhibitors against HIV-2Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration.Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.HIV-2 diagnosis and quantification in high-risk patients.Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West AfricaComplex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.Atazanavir: its role in HIV treatmentAntiretroviral drug resistance in human immunodeficiency virus type 2.Ritonavir-boosted protease inhibitors in HIV therapy.Special aspects of the treatment of HIV-2-infected patients.Determination of HIV tropism and its use in the clinical practice.New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System.Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.Performance of rapid tests for discrimination between HIV-1 and/or HIV-2 infections.Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.Analysis of the HIV-2 protease's adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet.
P2860
Q27676688-6FD1AD11-300E-4E4B-B68E-75CF52BC0F17Q30432689-B3618DD3-E2E4-4084-A4E5-E7F5C10C053EQ33869423-CA90EAFD-0425-4617-9486-837BCB708163Q33954546-87C36DC6-EF57-49B7-B9DE-7C19C00CD014Q33963958-E2CA8D7A-3A00-4936-94F5-2D1958475D26Q34052440-3D2F9BE4-2E17-433A-A7EB-A3BE388C64D3Q34058765-566D6BF9-798F-4DC4-A06B-052CF6B4527CQ34426605-B1CD8BA0-5EFD-4B20-A84E-9C9247DE8CEBQ34428902-35F1FA3C-4B8C-4FE9-A1EA-77AF555F7643Q34440391-02561BB0-AE42-4F3C-8241-19BC8AB65E92Q34730950-619704B8-162A-4E35-967D-7D5B53AE6C7BQ34742090-C8A68E85-175E-4242-A4B3-CE101A40BAE3Q35008562-9D4458C0-B29C-4A72-91D7-B137E06B7877Q35019924-1B5FEBDA-1437-44D2-93FF-D280B6623E6BQ35134947-C6A92915-5D6F-4EC6-90D0-C9DD3C1D6E7AQ35206272-E2B2CC3E-FE5E-4E75-9A55-B4F41DE2DCE2Q35445731-7CE15F71-EC6E-4999-93B7-F0E8BFE836E6Q35674666-90EB81E0-89A0-4B65-B01A-4AE8D0735EC2Q35738681-F47D3048-4457-4E96-9C5B-CCFA8C5B9345Q36097686-CA55525D-722C-4ACD-A043-357245346520Q36290647-8DC4810E-8914-4BDD-B486-9AD77A9C8FB0Q36564668-7DCD9E8E-9884-4FB6-8F27-8798110032F0Q36862541-8E24F030-C6B2-4BCE-B581-8604AEAB47F7Q36897863-A11DF598-A687-4AAE-A0FF-ADCE4DA0146FQ37026564-597F4E3E-C695-44A6-B2DB-D99D092D5C54Q37083896-29BF4B09-D68B-44A4-8B02-1BE7FE72D3FCQ37249418-D0C7E508-312B-47C6-B9F5-972277FE2BE1Q37496287-3FBF514B-306E-4972-BCA3-207439F1DC29Q37866319-CD03DA50-4B28-48B8-B4CC-9D298B3C56D8Q37979706-94B5998D-2FB1-42F9-A285-B08DF470E16BQ38160078-264E042F-B1EA-490C-B9DD-145444AEC629Q38682063-21C35FBE-D0FF-4FED-90A6-66C8809346B1Q38814591-F35D912A-C1FD-4945-BE6B-08420E3804FBQ38820118-25DA36F1-5CDD-47BC-BEC4-6C06213E6AA2Q38935015-D91B1BEC-3378-4217-97DB-27D80FC891B8Q39433148-BB36B717-305C-425B-BF79-B0DDFC6A1A89Q39533357-115D925B-4595-48C7-9718-35D11F093CFAQ41156500-033D38F5-CE9C-4E45-A585-A156B5D8C3EEQ44990505-05F4D701-24FB-4C47-85A2-F3E57F62CD60Q48240350-C3FD4575-2399-4B3B-87B3-9358BBA21BA4
P2860
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
In vitro phenotypic susceptibi ...... olates to protease inhibitors.
@ast
In vitro phenotypic susceptibi ...... olates to protease inhibitors.
@en
type
label
In vitro phenotypic susceptibi ...... olates to protease inhibitors.
@ast
In vitro phenotypic susceptibi ...... olates to protease inhibitors.
@en
prefLabel
In vitro phenotypic susceptibi ...... olates to protease inhibitors.
@ast
In vitro phenotypic susceptibi ...... olates to protease inhibitors.
@en
P2093
P2860
P50
P356
P1476
In vitro phenotypic susceptibi ...... olates to protease inhibitors.
@en
P2093
Antoine Bénard
Bénédicte Roquebert
Delphine Desbois
French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Gilles Collin
Pauline Campa
P2860
P304
P356
10.1128/AAC.01284-07
P407
P577
2008-01-28T00:00:00Z